- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01179854
Remegal Different Doses in Patients With Refractory Partial Seizures
May 10, 2017 updated by: Valexfarm
Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures
The purpose of this study is to determine weather different doses of Remegal are effective,safety and tolerant in Additional Therapy for Patients With Refractory Partial Seizures and pharmacokinetics definition
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Phase II
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barnaul, Russian Federation, 656022
- KGUZ "U.K. Erdman Altai Regional psychiatric hospital"
-
Ekaterinburg, Russian Federation, 620905
- Sverdlovsk Regional Hospital
-
Saransk, Russian Federation, 430030
- Republican Dispensary
-
Volgograd, Russian Federation, 400131
- GOU VPO Volgograd State medicine university of roszdrav
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject will report to have partial onset seizures for at least the last 2 years despite prior therapy with at least 2 different consecutive AEDs.
- Subject will report an average of at least 4 partial onset seizures per 28 days prior to entry in the Baseline phase.
- Seizure-free period will be no longer than 21 days in the 4-week period prior to entry in the Baseline phase.
- Subject will be on stable dosage regimen of a maximum of 3 AEDs,.
- The dosage of concomitant AED therapy will be kept constant for at least 4 weeks prior to entry into the Baseline phase.
- 'Subject will receive information will be given time to think about their participation and will give their written informed consent.
- Subject will be male or female between 18 and 65 years old.
Subject will have a diagnosis of epilepsy with simple partial seizures and/or complex-partial seizures both with or without secondary generalization according to the ILAE (1981):
- The results of at least one prior electroencephalogram (EEG) and magnetic resonance imaging/computerized tomography scan should be consistent with the diagnosis of partial seizures.
- In the case of simple partial seizures, only those who motor signs will be included.
Exclusion Criteria:
- Subject with non-epileptic events including psychogenic seizures that could be confused with seizures.
- Subject with seizures that cannot be counted due to clustering.
- Subject with a history of primary generalized seizures.
- Subject with a history of status epilepticus within the 12 months period prior to trial entry.
- Subject with concomitant treatment of felbamate or previous felbamate therapy within the last 6 months prior to trial entry.
- Subject with concomitant treatment of vigabatrin. Subjects with previous vigabatrin therapy must have had a visual field test prior to trial entry.
- Subject with a progressive structural lesion in the central nervous system or a progressive encephalopathy.
- Subject who received REMEGAL in a previous trial.
- Subject currently participating or who participated within the last two months in any trial of an investigational drug or experimental device.
- Pregnant or nursing women and/or those of childbearing potential who are not surgically sterile, two years postmenopausal or do not practice two combined methods of contraception, unless sexually abstinent, during the duration of the trial.
- Subject with any medical or psychiatric condition, which in the opinion of the investigator could jeopardize the subject's health or would compromise the subject's ability to participate in this trial.
- Subject with a history of chronic alcohol or drug abuse within the previous 2 years.
- Subject with alanine amino transferase (ALT), aspartate amino transferase (AST), alkaline phosphatase, total bilirubin, or serum creatinine level more than or equal to 2 times the upper limit of normal.
- Subject with clinically significant abnormal vital signs.
- Subject with a known history of severe anaphylactic reaction or serious blood dyscrasias.
- Subject with any other clinically significant disease, surgical condition or recent chronic consumption of non-AED medications (within the preceding four weeks prior to trial entry) that might reasonably have been expected to interfere with drug absorption, distribution, metabolism or excretion.
- Subject taking one of the following medications influencing the central nervous system within four weeks prior to trial entry: neuroleptics, monoamine oxidase (MAO) inhibitors, anxiolytics, amphetamines, sedative antihistamines, tranquilizers, hypnotics, narcotic analgesics, except for medication taken as epileptic treatment.
- Subject with confirmed clinically significant abnormality in ECG, including prolonged QTc interval.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Drug/ placebo
Other Names:
|
Experimental: 500 mg
Group of active treatment of Remegal 500 mg
|
Drug/ placebo
Other Names:
|
Experimental: Remegal 750 mg
Group of active treatment of Remegal 750 mg
|
Drug/ placebo
Other Names:
|
Experimental: Remegal 1000 mg
Group of active treatment of Remegal 1000 mg
|
Drug/ placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
safety and tolerability
Time Frame: Jan 2010 - Dec 2010
|
The primary objective of the study is to evaluate the safety and tolerability of Remegal administered concomitantly with 1 - 3 antiepileptic drugs (AEDs) in subjects who currently have uncontrolled partial seizures with or without secondary generalization.
|
Jan 2010 - Dec 2010
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy
Time Frame: Jan 2010 - Dec 2010
|
To assess the efficacy and its association with the Remegal dosages, and to evaluate the steady-state plasma concentrations of Remegal and concomitantly orally administered AEDs
|
Jan 2010 - Dec 2010
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dorogov Nikolay, MD, PhD, MUZ"City Clinic №4"
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
November 1, 2010
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
July 30, 2010
First Submitted That Met QC Criteria
August 10, 2010
First Posted (Estimate)
August 11, 2010
Study Record Updates
Last Update Posted (Actual)
May 11, 2017
Last Update Submitted That Met QC Criteria
May 10, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2Р/КИ/Б (Other Identifier: Valexfarm)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Self Efficacy
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingFall Injury | Falls | Exercise Self-Efficacy | Falls Self-EfficacyUnited States
-
Central South UniversityCompletedSelf Efficacy | Self-management
-
IRCCS Policlinico S. DonatoNot yet recruitingSelf Efficacy | Self Confidence | Anticoagulants
-
Kolding SygehusCompleted
-
Beni-Suef UniversityUnknown
-
Tuğba SarıCompleted
-
Karolinska InstitutetCompleted
-
The New SchoolUniversity of ZurichActive, not recruitingSelf EfficacyUnited States
-
Pacific Northwest University of Health SciencesAmerican Association of Colleges of Osteopathic Medicine - AACOMCompleted
-
University of Vic - Central University of CataloniaCompleted
Clinical Trials on Remegal
-
ValexfarmCompletedEpilepsy | Complex Partial Seizures | Simple Partial Seizures | Partial Seizures With Secondary GeneralizationRussian Federation